Table 1 Synergy score of LZX-2-73 combination with several chemotherapeutic agents.

From: Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models

Cancer cell line

Synergy score between LZX-2-73 and chemotherapeutic agents

SN38

Oxaliplatin

Gemcitabine

Paclitaxel

5-FU

Sorafenib

MIAPaCa-2

24.5

4.1

10.8

19.6

−0.3

23.2

PDAC056T

4.8

1.0

−1.9

−4.0

3.4

12.2

PDAC079T

4.8

−1.5

1.3

4.0

1.5

8.4

PDAC088T

5.0

0.7

−5.8

−2.9

3.0

16.2

PDAC018T

16.5

−2.8

4.1

−3.0

3.6

10.8

PC-3

−1.4

−4.1

0

−10.5

6.5

16.8

HT-29

24.2

−1.7

3.2

16.9

−4.9

17.6

H358

19.7

−0.3

1.8

14.3

5.3

18.6

H1299

14.4

−4.2

13.9

20.4

−1.9

22.3

MCF-7

33.6

2.4

10.8

6.2

16.8

42.1

MDA-MB-231

17.3

5.9

4.6

15.3

4.0

19.0

Jurkat

2.4

−2.2

−5.2

−3.7

0.8

11.4

Daudi

1.0

−10.7

−1.6

−2.4

−5.4

−4.7

U87

8.8

−2.5

1.0

7.0

−6.6

14.7

HepG2

8.4

3.5

4.1

6.2

6.0

17.3

Hep3B

20.2

0.3

4.9

23.7

4.3

13.9

  1. Different cell lines and patient-derived primary cultures were co-treated with the NUPR1 inhibitor LZX-2-73 and SN38, oxaliplatin, gemcitabine, paclitaxel, 5-FU, and sorafenib for 72 h. Cell viability was determined using SynergyFinder software. The Synergy score was determined according to the HSA model. A synergy score below −10 indicated antagonistic interactions, scores between −10 and 10 indicated additive interactions, and scores above 10 indicated synergistic interactions.